Cargando…

How the use of vaccines outside the cold chain or in controlled temperature chain contributes to improving immunization coverage in low- and middle-income countries (LMICs): A scoping review of the literature

BACKGROUND: Most vaccines are recommended for storage at temperatures of +2°C to +8°C to maintain potency. Immunization supply chain bottlenecks constraints reaching populations with life-saving vaccines. The World Health Organization permits the use of vaccines outside the cold chain as “controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Dadari, Ibrahim K, Zgibor, Janice C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society of Global Health 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915947/
https://www.ncbi.nlm.nih.gov/pubmed/33692889
http://dx.doi.org/10.7189/jogh.11.04004
Descripción
Sumario:BACKGROUND: Most vaccines are recommended for storage at temperatures of +2°C to +8°C to maintain potency. Immunization supply chain bottlenecks constraints reaching populations with life-saving vaccines. The World Health Organization permits the use of vaccines outside the cold chain as “controlled temperature chain (CTC)” upon meeting certain conditions and has set targets to license more vaccines CTC by 2020. OBJECTIVES: This scoping review aims to explore and synthesize the evidence in the literature on how the use of vaccines outside the cold chain or in a controlled temperature chain increases immunization coverage in low and middle-income countries (LMICs), with a focus on the timelines of the Global Vaccine Action Plan (2011-2020). METHODS: A systematic search of three online databases (PubMed, Embase, and Web of Science) due to their broad coverage of global health sciences retrieved 173 original peer-reviewed articles, of which 13 were included in the review having met our inclusion criteria. RESULTS: The majority of the studies were conducted in Africa (n = 9), followed by Asia (n = 3), and the least in the Pacific (n = 1). The different study designs captured included four non-randomized trials, three randomized trials, two simulation models, two cross-sectional studies, and one cohort study. Reported benefits included increased coverage, logistical ease, cost savings while vaccines remain potent. CONCLUSION: Currently, only two vaccines have been licensed to be stored CTC. More needs to be done to get additional vaccines licensed for CTC and disseminate operational guidance to operationalize its use in low- and middle-income countries.